DEFA14A: GlycoMimetics to Acquire Crescent Biopharma in All-Stock Deal, Secures $200 Million Financing

GlycoMimetics will acquire Crescent Biopharma, pivoting to solid tumor therapeutics with a $200 million financing to advance Crescent's pipeline.

Summary

• GlycoMimetics, Inc. has entered into an acquisition agreement with Crescent Biopharma, Inc., a privately held biotechnology company focused on solid tumor therapeutics.
• Upon completion of the transaction, the combined company will operate under the name Crescent Biopharma, Inc.
• A syndicate of investors has committed $200 million to purchase GlycoMimetics common stock and pre-funded warrants to support the acquisition.
• The transaction is expected to close in the second quarter of 2025, with the financing closing immediately afterward.
• The company's cash balance at closing is anticipated to fund operations through 2027.
• Pre-acquisition GlycoMimetics stockholders are expected to own approximately 3.1% of the combined company, while pre-acquisition Crescent stockholders are expected to own approximately 96.9%.
• The percentage ownership is subject to adjustment based on GlycoMimetics' net cash at closing.
• The combined company will be led by Jonathan Violin, Ph.D., Crescents interim Chief Executive Officer.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the acquisition provides a new direction and funding, it also involves a significant shift in ownership and reliance on a new pipeline. The failure of the uproleselan trial tempers enthusiasm.

Positives

• The acquisition provides GlycoMimetics with a new focus on solid tumor therapeutics.
• The $200 million financing provides substantial capital to advance Crescent's pipeline.
• Crescent's lead program, CR-001, has a promising mechanism of action and is expected to have preliminary proof of concept data in 2H26.
• The combined company is expected to have a cash runway through 2027.

Negatives

• GlycoMimetics stockholders will own a small percentage (approximately 3.1%) of the combined company.
• The transaction is subject to stockholder approval and customary closing conditions, which could delay or prevent the closing.

Risks

• The transaction is subject to stockholder approval and customary closing conditions.
• The combined company's success depends on the successful development and commercialization of Crescent's pipeline.
• Clinical trials may not be successful, and regulatory approvals may not be obtained.
• The combined company may face competition from other companies developing solid tumor therapeutics.
• The combined company may require additional capital in the future.

Future Outlook

The combined company will focus on advancing Crescent's pipeline of oncology therapeutics, with CR-001 expected to have preliminary proof of concept data in 2H26. The financing is expected to fund operations through 2027.

Management Comments

• Jonathan Violin: 'This transaction and financing enable a potentially rapid development path for CR-001, and for the antibody drug conjugate programs CR-002 and CR-003.'
• Harout Semerjian: 'We are confident that our transaction with Crescent represents a significant opportunity for GlycoMimetics and its stockholders.'

Industry Context

The announcement reflects a trend of companies focusing on specific therapeutic areas to enhance their pipelines and attract investment. The focus on solid tumors and the use of bispecific antibodies and ADCs are areas of active interest in the oncology field.

Comparison to Industry Standards

• CR-001 is benchmarked against ivonescimab, which demonstrated superior efficacy compared to pembrolizumab in a Phase 3 trial.
• Crescent's ADC programs (CR-002 and CR-003) utilize topoisomerase inhibitor payloads, which have shown improved efficacy and safety compared to ADCs with alternative payloads like auristatins, as seen in Enhertu vs. Kadcyla.

Stakeholder Impact

• GlycoMimetics stockholders will have a reduced ownership stake in the combined company.
• The combined company will focus on solid tumor therapeutics, potentially impacting the development of GlycoMimetics' existing pipeline.
• The $200 million financing provides resources to advance Crescent's pipeline, potentially benefiting patients with solid tumors.

Next Steps

• Obtain stockholder approval for the transaction.
• Satisfy customary closing conditions.
• Close the transaction, expected in the second quarter of 2025.
• Close the $200 million financing immediately following the transaction.
• Advance Crescent's pipeline, with CR-001 expected to have preliminary proof of concept clinical data in 2H26.

Key Dates

Keywords

Crescent Biopharma, GlycoMimetics, Merger, Acquisition, Financing, Oncology, Solid Tumors, CR-001, Bispecific Antibody, Uproleselan